SCTX · Scribe Therapeutics, Inc.
$21.89
+1.06 (+5.06%)
At close · Aug 4
Market Cap
$337.15M
Shares
16.18M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.84
Open$20.16
Day$19.40–21.00
52W$17.20–25.49
Avg vol 30d359K
Short vol64%
DataJul 2026–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Limited
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
High
Market backdrop
VIX 15.9 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
52-week position
44%
mid-range
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$71.3M over 90 days · 0% sells
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
138%
annualized · 1-yr
Max drawdown
−17%
past year
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
52-week position
44%
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$71.3M over 90 days · 0% sells
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $17
Now $21 · 44%
52-wk high $25
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SCTX
this stock
Scribe Therapeutics, Inc.
|
$337.15M | — | — | — | — |
|
ONC
BeOne Medicines Ltd.
|
$453.48B | +3.3% | +22179.2% | 922.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.47B | +3.8% | +46.2% | 27.9 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$78.17B | -1.5% | +20.8% | 18.8 | 3.4% |
|
ARGX
Argenx SE
|
$51.98B | -1.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Smart Money
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SCTX | +10.5% | — | — | +7.0% | — |
| SPY | +2.5% | +0.9% | +9.2% | +1.4% | +11.1% |
| vs SPY | +8.0% | — | — | +5.5% | — |